Current policies being employed to limit spending can have serious consequences for patients, but a different benefit design approach could present an alternative strategy.
Current policies being employed to limit spending can have serious consequences for patients. In the April issue of The American Journal of Managed Care® (AJMC®), A. Mark Fendrick, MD, co-authored a paper that examined the relationship between consumer cost sharing for branded antidepressants and the initiation of branded therapy among patients who were filling a prescription for a generic medication to treat major depressive disorder.
Read the paper:
Listen above or through one of these podcast services:Cost Sharing and Branded Antidepressant Initiation Among Patients Treated With Generics